羟苯磺酸钙联合雷珠单抗治疗糖尿病视网膜病变黄斑水肿的临床疗效

The Clinical Effect of Calcium Dobesilate Combined with Ranibizumab in the Treatment of Diabetic Retinopathy and Macular Edema

目的探讨对糖尿病视网膜病变黄斑水肿患者采用羟苯磺酸钙+雷珠单抗完成治疗后获得临床效果。方法选取2018年1月-2020年12月收治的53例糖尿病视网膜病变黄斑水肿患者进行药物治疗研究;随机分为单一用药组26例(采用雷珠单抗完成药物治疗)和联合用药组27例(采用羟苯磺酸钙+雷珠单抗完成药物治疗);比较两组患者用药总有效率、黄斑中心视网膜厚度、最佳矫正视力。结果联合用药组药物治疗总有效率(92.59%)高于单一用药组,差异有统计学意义(P<0.05);治疗前,两组患者黄斑中心视网膜厚度、最佳矫正视力比较,差异无统计学意义(P>0.05);治疗后,联合用药组黄斑中心视网膜厚度(274.55±50.39)μm低于单一用药组,最佳矫正视力(0.40±0.04)高于单一用药组最佳矫正视力(0.26±0.02),两组比较差异有统计学意义(t=9.554、16.018,P<0.05)。结论羟苯磺酸钙+雷珠单抗药物联合应用后,观察患者用药总有效率、黄斑中心视网膜厚度、最佳矫正视力均获得显著改善,可促进糖尿病视网膜病变黄斑水肿患者总体用药水平、预后水平显著提升。

Objective To investigate the clinical effect of calcium dob sulfonate+leizumab in the treatment of diabetic retinopathy with macular edema.Methods Selected 53 patients with diabetic retinopathy and macular edema who were admitted from January 2018 to December 2020 for drug treatment research;randomly divided into single medication group(using ranibizumab to complete drug treatment)and combination medication group(using calcium dobesilate+ranibizumab to complete drug treatment),corresponding to 26 cases and 27 cases respectively;the total effective rate of medication,the thickness of the retinal center of the macula,and the best corrected visual acuity were compared between the two groups of patients.Results The total effective rate(92.59%)in combination medication group was higher than that in single medication group,and the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in macular central retinal thickness and best corrected visual acuity between two groups(P>0.05).After treatment,the macular central retinal thickness(274.55±50.39)μm in the combination medication group was lower than that in the single medication group,and the best corrected visual acuity(0.40±0.04)was higher than that in the single medication group(0.26±0.02),the difference between the two groups was statistically significant(t=9.554,16.018,P<0.05).Conclusion After the combined application of calcium doB sulfonate+lezumab,the total effective rate,central macular retinal thickness and best corrected visual acuity of the patients were observed to be significantly improved,which can promote the overall medication level and the prognosis of patients with diabetic retinopathy and macular edema.